Patient Demographics
| Center 1 | Center 2 | Center 3 | Total | p-value | |
|---|---|---|---|---|---|
| N (%) | 225 (21.8) | 448 (43.4) | 359 (34.8) | 1032 (100.0) | n/a |
| Baseline study period | 9/8/2010-10/25/2011 | 1/1/2011-12/31/2011 | 1/1/2010-4/30/2011 | ||
| Final Study period | 10/31/2011-2/25/2013 | 1/1/2012-12/31/2013 | 5/1/2011-3/30/2012 | ||
| Mean Age Years (SD) | 6.6 (4.3) | 6.4 (4.3) | 7.6 (5.0) | 6.9 (4.6) | 0.002 |
| Female | 122 (54.2) | 179 (40.0) | 163 (45.4) | 464 (45.0) | <0.001 |
| Race | <0.001 | ||||
| African American | 40 (17.8) | 36 (8.0) | 21 (5.8) | 97 (9.4) | |
| Caucasian | 128 (56.9) | 363 (81.0) | 320 (89.1) | 811 (78.6) | |
| Hispanic | 15 (6.7) | 0 (0.0)1 | 0 (0.0)1 | 15 (1.5) | |
| Asian | 5 (2.2) | 10 (2.2) | 2 (0.6) | 17 (1.6) | |
| Other | 37 (16.4) | 39 (8.8)1 | 16 (4.5)1 | 92 (8.9) | |
| Diagnosis | <0.001 | ||||
| ALL2 | 104 (46.2) | 240 (53.6) | 131 (36.5) | 475 (46.0) | |
| AML3 | 5 (2.2) | 6 (1.3) | 4 (1.1) | 15 (1.5) | |
| Brain Tumor | 23 (10.2) | 29 (6.5) | 28 (7.8) | 80 (7.8) | |
| Lymphoma | 26 (11.6) | 24 (5.4) | 46 (12.8) | 96 (9.3) | |
| Neuroblastoma | 19 (8.4) | 22 (4.9) | 45 (12.5) | 86 (8.3) | |
| Sarcoma | 21 (9.3) | 55 (12.3) | 44 (12.3) | 120 (11.6) | |
| Wilm's Tumor | 8 (3.6) | 16 (3.6) | 2 (0.6) | 26 (2.5) | |
| Other | 19 (8.4) | 56 (12.5) | 59 (16.4)2 | 134 (13.0)4 | |
| Type of Line | <0.001 | ||||
| PICC | 14 (6.2) | 15 (3.3) | 15 (4.2) | 44 (4.3) | |
| Port | 172 (76.4) | 370 (82.6) | 250 (69.6) | 792 (76.7) | |
| Broviac | 30 (13.3) | 52 (11.6) | 56 (15.6) | 138 (13.4) | |
| Other | 0 (0.0) | 10 (2.2) | 38 (10.6) | 48 (4.7) | |
| Multiple | 3 (1.3) | 1 (0.2) | 0 (0.0) | 4 (0.4) | |
| None | 6 (2.7) | 0 (0.0) | (0.0) | 6 (0.6) | |
| Time of visit | 0.547 | ||||
| Weekend | 105 (46.7) | 182 (40.6) | 131 (36.5) | 418 (40.5) | |
| Weekday | 120 (53.3) | 266 (59.) | 228 (63.5) | 614 (59.5) | |
| 8AM-4PM | 58 (25.8) | 132 (29.5) | 117 (32.6) | 307 (29.7) | |
| 4PM-12AM | 121 (53.8) | 229 (51.1) | 173 (48.2) | 523 (50.7) | |
| 12AM-8AM | 46 (20.4) | 87 (19.4) | 69 (19.2) | 202 (19.6) | |
| EMLA/LMX5 applied in ED on port devices | 78/172 (45.3) | 143/370 (38.6) | 92/250 (36.8) | 313/792 (39.5) | 0.188 |
| Documented Line Infection | 40 (17.9) | 24 (5.4) | 55 (15.3) | 119 (11.5) | <0.001 |
| Admit | 224 (100)6 | 259 (57.8) | 246 (68.5) | 729 (70.7) | <0.001 |
| Admit To PICU | 8 (3.6) | 20 (7.7) | 10 (2.8) | 38 (3.7) | 0.451 |
1Hispanic included in “other” at these institutions
2ALL: Acute Lymphoblastic Leukemia
3AML: Acute Myeloid Leukemia
4One diagnosis not listed
5EMLA=Eutectic mixture of local anesthetics. LMX=Topical lidocaine anesthetic
6Site 1 policy to admit all children with fever and cancer